Modern aspects of peptide immuno-modulating agent use in the system of vaccinal prevention and vaccinal therapy

The use of peptide immuno-modulating agents for vaccinal prevention in population does not have practical application for a number of reasons. At the first place it is related to the fact that occurence of postprimary immunodeficient condition in subjects who must be vaccinated normally does not lead to significant decrease of spesific immune response and is not considered to be contradiction to vaccination. Therefore, perspective of immuno-modeling agent use in the system of vaccinal prevention can be based on the use of such agents as medicamentous «cover» for post-vaccinal period to decrease undesired viccanal reactions, prevention of some post-vaccinal complications, reduction of number of contradictions to vaccination among specific groups of people with some chronic conditions, or to stimulate earlier protective immune response among risk groups: children with hemoblastosis when immediate and regular blood transfusion is needed, newborns of viral hepatitis B mothers, and generally healthy people in need of immediate vaccinal prevention in site of infection.